The price of Precigen Inc. (NASDAQ:PGEN) shares last traded on Wall Street rose 13.53% to $1.72.
Based on available information, 5 analysts follow Precigen Inc. (NASDAQ:PGEN). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $14.00 and a low of $6.00, we find $9.00. Given the previous closing price of $1.51, this indicates a potential upside of 496.03 percent. PGEN stock price is now 38.27% away from the 50-day moving average and 24.23% away from the 200-day moving average. The market capitalization of the company currently stands at $433.68M.
Among analysts, 1 rate the stock a hold while 4 rate it a buy. Brokers who have rated the stock have averaged $9.50 as their price target over the next twelve months.
In other news, KIRK RANDAL J, Director bought 119,411 shares of the company’s stock on Aug 16. The stock was bought for $180,311 at an average price of $1.51. Upon completion of the transaction, the Director now directly owns 31,837,786 shares in the company, valued at $54.76 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 15, Director KIRK RANDAL J bought 380,589 shares of the business’s stock. A total of $577,301 was incurred on buying the stock at an average price of $1.52. This leaves the insider owning 31,718,375 shares of the company worth $54.56 million. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PGEN stock. A new stake in Precigen Inc. shares was purchased by EMFO, LLC during the first quarter worth $273,000. EXCHANGE TRADED CONCEPTS, LLC invested $163,000 in shares of PGEN during the first quarter. In the first quarter, PENDAL GROUP LTD acquired a new stake in Precigen Inc. valued at approximately $150,000. Y-INTERCEPT (HONG KONG) LTD acquired a new stake in PGEN for approximately $121,000. AMERICAN FINANCIAL GROUP INC purchased a new stake in PGEN valued at around $100,000 in the second quarter. In total, there are 218 active investors with 60.50% ownership of the company’s stock.
A candlestick chart of Precigen Inc. (NASDAQ: PGEN) showed a price of $1.5700 on Thursday morning. During the past 12 months, Precigen Inc. has had a low of $0.81 and a high of $2.90. The fifty day moving average price for PGEN is $1.2524 and a two-hundred day moving average price translates $1.3851 for the stock.
The latest earnings results from Precigen Inc. (NASDAQ: PGEN) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.08, beating analysts’ expectations of -$0.1 by 0.02. This compares to $0.04 EPS in the same period last year. The company reported revenue of $1.77 million for the quarter, compared to $2.91 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -39.3 percent. For the current quarter, analysts expect PGEN to generate $1.98M in revenue.
Precigen Inc.(PGEN) Company Profile
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. The company operates through two segments, Biopharmaceuticals and Exemplar. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and Lactococcus lactis, a food-grade bacterium. Additionally, it provides RheoSwitch Therapeutic System, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
